Secondary prevention in coronary heart disease: goal achievement and drug prescribing.
OBJECTIVE
To provide an overview of the degree of treatment goal achievement and drug prescribing in patients with coronary heart disease (CHD) in clinical practice.


METHODS
Patients undergoing planned or acute percutaneous coronary intervention (PCI) were included. Patients' medical records and the hospital's database on clinical chemistry analyses were studied retrospectively.


METHODS
Goal achievement and drug prescription relative to published therapeutic guidelines.


RESULTS
A total of 200 patients aged 66 +/- 11 years were included. Blood pressure <140/90 mmHg was achieved in 36% of patients 3 months after PCI and total cholesterol <5 mmol/l was achieved in 29% at the time of PCI. Three months after PCI the patients were on 1.4 (range 0-4) drugs with antihypertensive effect (including diuretics). Seventy eight percent were on a statin, 92% were on low-dose aspirin, and 23% had a diuretic in their drug regimen. Five out of 16 patients with diabetes mellitus included in the study were prescribed an angiotensin converting enzyme-inhibitor (ACE-I).


CONCLUSIONS
There is probably a potential for increased degree of goal achievement and for improved drug prescribing in patients with CHD undergoing PCI at our hospital.
Giverhaug
Trude
T
Institute of Pharmacy, Faculty of Medicine, University of Tromsø, N-9037, Tromsø, Norway. trudeg@farmasi.uit.no
Bruland
Christine
C
Trovik
Thor
T
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D003327:Coronary Disease / Q000517:prevention & control* / Q000628:therapy; D004232:Diuretics / Q000627:therapeutic use; D011307:Drug Prescriptions; D004359:Drug Therapy, Combination; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D055502:Secondary Prevention
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin